65,437 trials
Type 2 Diabetic Peripheral Neuropathy (DPN)
Primary: Change From Baseline in Vibration Perception Threshold (VPT) at 24 Weeks — 32.16; 33.88; -1.96; -3.27 volts
Bronchopulmonary Dysplasia · Encephalomalacia · Premature Birth
Primary: Total Cerebral Volume as Measured by Volumetric Brain MRI — 272.01; 277.82 cm^3
Stimulant Dependence
Primary: Stroop Color-word Task — 55.4; 50.5 seconds
Parkinson Disease
Primary: Incidence of AE/SAE — 5.16 Percentage of participants
Acute Decompensated Heart Failure
Primary: Renal Function by Serum Creatinine — 1.3; 1.3; 1.3; 1.4 mg/dL
HIV Infections · Hepatitis C · HCV Infection
Primary: Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial…
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Alopecia · Alopecia, Androgenetic · Baldness
Primary: Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost — 0.552; 1.77; 5.58 Picograms/Milliliter (pg/mL)
Tobacco Use Cessation
Primary: Abstinence Rate — 8; 10 participants
Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Objective Response — 4; 7 participants
Head and Neck Cancer · Lung Cancer · Liver Cancer
Primary: Reproducibility of [F18]HX4 PET Imaging in Measuring Hypoxia in Tumors — 39 participants — p=<0.001
Asthma
Primary: Relationship Between FeNO and the Diagnosis of Asthma — 1; 1; 1 participants
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Allergic Rhinitis
Primary: Baseline Adjusted Area Under the Curve (AUC) of Minimal Cross-Sectional Area (MCA) of Nasal Cavity by Acoustic Rhinometry — -0.682; -0.504; -0.550 square centimeter*hour…
Prostatic Neoplasms
Primary: Number of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12 — 10; 25 Participants